SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02425904
Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene
This research study is evaluating a drug called clofarabine as a possible treatment for
Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.
Name: Clofarabine
Description: Evaluation of response to clofarabine
Type: Drug
Group Labels: 2 1-Recurrent or Refractory LCH 2-LCH-related disorders
Primary Outcomes
Description: Responses will be assessed using the standard criteria proposed by the Histiocyte Society
Measure: Overall Response Rate
Time: Week 7
Secondary Outcomes
Measure: Progression Free Survival Time: At three and five years
Measure: Overall Survival Time: At three and five years
Measure: The proportion of patients who experience a toxicity-event requiring stopping clofarabine Time: Baseline, Up to 24 weeks
Measure: Proportion of participants with grade 3-4 toxicity Time: Baseline, Up to 24 Weeks
Purpose: Treatment
Allocation: Non-Randomized
Single Group Assignment
There is one SNP
SNPs
1 V600E
ECD patients
who have confirmed BRAF V600E mutation must have failed treatment with a BRAF
inhibitor or are not considered to be eligible for such treatment. --- V600E ---